UOC
JSPR icon

UBS O'Connor’s Jasper Therapeutics JSPR Stock Holding History

UBS O'Connor’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,625
Closed -$4.57M – 862
2020
Q4 		$4.57M Hold
45,625
– – 0.09% 253
2020
Q3 		$4.54M Sell
45,625
-11,375
-20% -$1.14M 0.12% 117
2020
Q2 		$5.84M Sell
57,000
-3,000
-5% -$293K 0.13% 146
2020
Q1 		$5.7M Buy
+60,000
New +$5.87M 0.12% 133

Other funds holding JSPR

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return

UBS O'Connor's JSPR Position: Q1 2021 in Review

UBS O'Connor sold out of Jasper Therapeutics (JSPR) in Q1 2021, closing a stake of 45,625 shares — an estimated $4.57M sold.

UBS O'Connor first reported a position in JSPR in Q1 2020 and held it in 4 quarters. The position peaked at $5.84M in Q2 2020. 53 funds tracked by Wall St. Rank hold JSPR as of Q1 2021.

  • UBS O'Connor reported no remaining Jasper Therapeutics position as of Q1 2021 after selling out during the quarter.
  • UBS O'Connor sold 45,625 Jasper Therapeutics shares in Q1 2021, an estimated $4.57M.
  • UBS O'Connor first reported a position in Jasper Therapeutics in Q1 2020 and held it in 4 quarters.
  • UBS O'Connor's Jasper Therapeutics position peaked at $5.84M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2021.

Based on UBS O'Connor's 13F filing for Q1 2021, filed 14 May 2021.